Navigation Links
AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance

TUSTIN, Calif., Nov. 12 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), a vertically integrated pharmaceutical company with operations in China and the US, announced today preliminary third quarter earnings and revised 2008 guidance information.

For the third quarter of FY2008, AMDL expects gross sales to be approximately $12.4 million and net sales after sales promotions of approximately $9.2 million. Gross profit is expected to be approximately $4.9 million and income from operations to be approximately $2.3 million. The Company expected net income before currency translation to be approximately $1.6 million.

Earnings were originally projected to be approximately $3.4 million. However, the Company made a strategic decision to offer promotional discounts of $3.2 million to promote new product sales in the Chinese marketplace, primarily for the newly released formulations of AMDL's best-selling Goodnak(R) anti-aging product line. The existing promotional discounts will carry forward into the fourth quarter of 2008 and the first quarter of 2009. Based upon this information, AMDL continues to anticipate targeted gross sales of approximately $32 to $36 million for 2008. With regards to earnings guidance, the Company now estimates net income before foreign currency translation to be between $1.8 and $ 2.2 million for FY2008.

"We're operating AMDL for long-term success in a period of accelerated growth," said AMDL's Chairman and newly appointed CEO Mr. Douglas MacLellan. "We made a strategic and conscious decision to provide sales promotion discounts for certain new products in the third and fourth quarters which we believe will accelerate the introduction and market penetration. Specifically, sales promotion discounts incurred this quarter are the result of a promotion campaign to expand AMDL's sales footprint for newly released formulation of our Goodnak anti-aging line -- AMDL's highest profit margin product line. This is an investment and important part of our marketing strategy to increase sales revenue; bolster AMDL's competitive position in China and new markets and to drive long-term growth for the Company & our shareholders."

AMDL will discuss its business outlook during its regular quarterly conference call which is scheduled for the end of November. Specific details will be announced later this month.

Mr. MacLellan continued, "With the recent adjustments made in our business -- including an expanded and strengthened senior management team and board of directors, revised business strategy, and prioritized focus on securing additional capital to support AMDL's future growth -- we have embarked on the most exciting era in the Company's history. What lies ahead is the perfect opportunity to establish AMDL as a market-winning leader that delivers lucrative, long-term returns for our employees, partners, customers and shareholders."

Mr. MacLellan will cover today's news in a scheduled presentation he will deliver at Rodman & Renshaw's Annual Global Investment Conference taking place today, November 12th, 2008 at the New York Palace Hotel in New York City. Additionally, interested parties can download a copy of Mr. MacLellan's presentation through the AMDL corporate website located under the "news" section. For additional information please contact Kristine Szarkowitz, SVP, AMDL Investor Relations at 206-310-5323 or

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 490 people in the U.S. and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties related to the Company's access to additional capital, competition and dependence on key management.

AMDL Contact:

Kristine Szarkowitz

Director-Investor Relations

(Tel:) 206. 310.5323

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
2. Standard & Poors Announces Changes to U.S. Indices
3. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
4. Cardiums InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
5. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
6. China Biologic Products Announces Third Quarter 2008 Results Conference Call
7. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
8. Heritage Labs Announces A1c Test Certification Milestone
9. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
10. The Binding Site Announces Trading Update for Year Ended September 30th 2008
11. CorMatrix Announces Pre-Clinical Data Suggesting Next Generation ECM Technology(TM) Can Improve Cardiac Function
Post Your Comments:
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
(Date:11/25/2015)... LOS ANGELES and HOLLISTON, Mass. ... Regenerative Technology, Inc. (Nasdaq: HART ), a biotechnology ... announced that CEO Jim McGorry will present ... Tuesday, December 1, 2015 at 2:30 p.m. PT. The ... (link below) for 30 days. Management will also be ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
Breaking Biology Technology:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
Breaking Biology News(10 mins):